• Age ≥ 18 years old at first prescription of icodextrin, male or female;

• With a definite diagnosis of CRF and on maintenance PD ≥ 3 months;

• On CAPD treatment;

• Being treated with icodextrin long dwell exchange with an icodextrin prescription ≤ 6 months with essential baseline information(including age, gender, PD vintage, presence of diabetes or not, PET, and assessment of dialysis adequacy);

• Voluntarily sign the informed consent form (ICF) and be willing to complete the study visits as required by the investigator (For death cases, exemption of the informed consent will be applied with approval of the ethics committee).

• Age ≥ 18 years old, male or female;

• Patients with a definite diagnosis of CRF and on maintenance PD ≥ 3 months;

• On CAPD treatment, with planned prescription for icodextrin;

• Voluntarily sign the ICF and be willing to complete the study visits as required by the investigator.

• Age ≥ 18 years at index date, male or female;

• Those with a definitive diagnosis of CRF prior to the index date and eligible for CAPD treatment with Baxter's glucose PD solutions between July 1, 2020 and December 31, 2020;

• On maintenance PD ≥ 3 months;

• Essential baseline information(including age, gender, PD vintage, presence of diabetes or not, peritoneal transport status);

• Any prescription of Baxter's glucose PD solutions and medical records of clinical events within 1 year from baseline.